Examples of using P-values in English and their translations into Romanian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
-
Programming
P-values compared to pamidronate.
For all other endpoints, the p-values correspond to a test of differences in hazard rates.
P-values are all adjusted p-values for multiplicity.
There was no evidence of period,sequence/carry-over effects in the ASCEND-PD study(p-values all> 0.10).
Note: p-values not controlled for multiple testing.
We will also report the number ofmethods(out of all 5) for combining p-values that result in a significant result at the-level of 0.05.
P-values for secondary endpoints based on Chi-squared test.
Median values from Kaplan-Meier analysis;HR and p-values from Cox regression models adjusting for important prognostic factors.
P-values for olanzapine and quetiapine XR vs. placebo were unadjusted.
Follow-up analysis was performed with a data cut-off date of 07 March 2014; all p-values are displayed for descriptive purpose only.
Pairwise comparison p-values:*= p< 0.05 for comparisons of etanercept vs.
However, these are artifacts due to the different assumptions of the methods for combining p-values, as can be clearly seen in Materials S1.
P-values represent each infliximab treatment group vs. AZA monotherapy.
For each subset of interest we performed this permutation-robustness test in each of the 12 datasets,obtaining 12 empirical(“permutation”) p-values.
P-values for comparison versus pre-Tx values were computed using paired t-tests.
And in accordance with recently implemented NEJM policies, the hazard ratio(HR) and its confidence interval(CI)were published, but no P-values were reported.
P-values were< 0.001 for both mTSS and erosion score and≤ 0.01 for JSN score.
Pre-Tx= Pre-treatment; SD= Standard Deviation; SDS= Standard Deviation Score[1] P-values for comparison versus pre-Tx values were computed using paired t-tests.
All p-values are pairwise comparisons of proportions for Humira versus placebo* p< 0.001** p< 0.01.
Clearly, these 12 data-sets are not independent measures,so the standard meta-analytical statistical tools for combining p-values[45],[46] cannot be used a priori.
All p-values adjusted for multiplicity of testing based on pre-defined hierarchy, except BASDAI 50 and ASDAS-CRP.
Erum calcium≥ 2.9 mmol/l was 30 to 40 days for patients treated with zoledronic acid versus 17 days for those treated with pamidronate 90 mg(p-values: 0.001 for 4 mg and 0.007 for 8 mg zoledronic acid).
Wald p-values are quoted for the comparison of treatments using logistic regression with factors for treatment and region.
All differences betweenLucentis 0.5 mg and the two control groups were statistically significant and clinically meaningful, with p-values ranging from 0.009 to< 0.0001.
For composite endpoints, the p-values correspond to a test of non-inferiority seeking to show that the hazard ratio is less than 1.3.
Median time to relapse(re-increase of albumin-corrected serum calcium≥ 2.9 mmol/ l) was 30 to 40 days for patients treated with Zometa versus 17 days for those treated with pamidronate 90 mg p-values.
Pairwise comparison p-values:†= p< 0.05 for comparisons of Enbrel+ methotrexate vs. methotrexate and= p< 0.05 for comparisons of Enbrel+ methotrexate vs.
Please note that this procedure, while guarding against false positives,does result in counterintuitive effects, such as the apparently dramatic lowering of the p-values when controlling for geography in some cases(for example, for America; see Table 2).
The p-values for ORR and Global Health Status/Quality of Life(QoL) scores are descriptive based on the pre-specified multiplicity adjustment plan.
In summary, we combined these empirical p-values from the 12 datasets using five methods, conservatively taking the largest p-value for the subset of interest to guard against false positives(see Tables 2 and Materials S1).